Research Analysts’ Recent Ratings Changes for Biohaven (BHVN)

Biohaven (NYSE: BHVN) has recently received a number of price target changes and ratings updates:

• 9/18/2026 – Biohaven had its “buy” rating reaffirmed by Citigroup Inc..
• 9/10/2026 – Biohaven had its “neutral” rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
• 9/8/2026 – Biohaven was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $19.00 price target on the stock, down from $23.00.
• 8/28/2026 – Biohaven had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 8/28/2026 – Biohaven was given a new $21.00 price target by Canaccord Genuity Group Inc..
• 8/27/2026 – Biohaven had its “neutral” rating reaffirmed by HC Wainwright.
• 8/26/2026 – Biohaven had its “buy” rating reaffirmed by TD Cowen.
• 8/26/2026 – Biohaven had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $30.00 price target on the stock.
• 8/12/2026 – Biohaven had its price target raised by Morgan Stanley from $18.00 to $19.00. They now have an “overweight” rating on the stock.
• 8/11/2026 – Biohaven had its price target raised by Royal Bank Of Canada from $22.00 to $23.00. They now have an “outperform” rating on the stock.

Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and immunological disorders. The company’s research programs use a range of approaches, including small-molecule medicines, biologics and other targeted therapies, with the goal of addressing diseases that have limited or inadequate treatment options.

Biohaven’s pipeline has included investigational treatments for conditions such as epilepsy, obsessive-compulsive disorder, neurodegenerative diseases, neuroinflammatory disorders and immune-mediated diseases.